This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Del Rio, M
Right arrow Articles by Shelton, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Del Rio, M
Right arrow Articles by Shelton, S

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1982 October; 22(4): 622-627

Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis.

M Del Rio, G H McCracken Jr, J D Nelson, D Chrane and S Shelton

ABSTRACT

Single-dose pharmacokinetics of ceftriaxone were determined in 19 patients with proven bacterial meningitis. The dosage was 50 mg of ceftriaxone per kg. The plasma concentration time curve declined in a biexponential manner. The mean peak plasma concentration was 207 micrograms/ml, and the elimination half-life was 4 h. In 12 patients, multiple-dose pharmacokinetics were determined after a loading dose of 75 mg of ceftriaxone per kg, followed by 50-mg/kg doses every 8 h in 5 patients or every 12 h in 7 patients. The mean peak plasma concentration was 230 micrograms/ml after the first dose and 263 micrograms/ml after the last dose. Of 12 patients, 5 had trough values that were larger after multiple doses than after a single dose. Mean penetration of ceftriaxone into cerebrospinal fluid was 3.1%. The median cerebrospinal fluid bactericidal titer against the patients pathogens was greater than 1:1,024 and less than 1:2,048. The drug was well tolerated without adverse effects.

Antimicrob Agents Chemother. 1982 October; 22(4): 622-627




This article has been cited by other articles:

  • Musher, D. M., Bartlett, J. G., Doern, G. V. (2001). A Fresh Look at the Definition of Susceptibility of Streptococcus pneumoniae to {beta}-Lactam Antibiotics. Arch Intern Med 161: 2538-2544 [Abstract] [Full Text]  
  • Kaplan, S. L., Mason Jr, E. O., Barson, W. J., Wald, E. R., Arditi, M., Tan, T. Q., Schutze, G. E., Bradley, J. S., Givner, L. B., Kim, K. S., Yogev, R. (1998). Three-Year Multicenter Surveillance of Systemic Pneumococcal Infections in Children. Pediatrics 102: 538-545 [Abstract] [Full Text]  
  • Jacobs, R. F., Wright, M. W., Deskin, R. L., Bradsher, R. W. (1988). Delayed Sterilization of Haemophilus influenzae Type b Meningitis With Twice-Daily Ceftriaxone. JAMA 259: 392-394 [Abstract]  
  • McCRACKEN, G. H. JR (1985). Use of Third-Generation Cephalosporins for Treatment of Neonatal Infections. Arch Pediatr Adolesc Med 139: 1079-1080 [Abstract]  
  • Steele, R. W., Bradsher, R. W. (1983). Ceftriaxone for the Treatment of Serious Infections. Arch Pediatr Adolesc Med 137: 1044-1047 [Abstract]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»